Multiple Myeloma
Multiple Myeloma is a cancer of the plasma cells, a type of white blood cell found in the bone marrow. It leads to the production of abnormal proteins that can cause various health issues, including bone pain and kidney problems.
Multiple Myeloma: Elranatamab Treatment Study
We are studying the effectiveness of Elranatamab for patients with relapsed or refractory multiple myeloma who have already been treated with three different drug classes. This trial aims to see if it can help achieve better disease control.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years or older?
- Do you have multiple myeloma that has relapsed after at least one treatment?
- Are you currently pregnant or breastfeeding?
- Have you had any major surgery in the last 14 days?
- Do you have any serious heart problems, like a recent heart attack or unstable angina?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Institut Catala D'oncologia
Oncology
Badalona, Spain
Son Llatzer Hospital
Oncology
Can Pastilla, Spain
Hospital Universitario Hm Sanchinarro
Oncology
Chamartín, Spain
Sponsor: Pethema Fundacion
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.